Moderna (MRNA) Other Non-Current Liabilities (2017 - 2026)
Moderna (MRNA) posted quarterly Other Non-Current Liabilities of $284.0 million for Q2 2026, up 2.9% year-over-year from $276.0 million in Q2 2025, and little changed on a QoQ basis from $283.0 million in Q1 2026.
Moderna (MRNA) Other Non-Current Liabilities (2017 - 2026) Analysis & Trends
Moderna has reported Other Non-Current Liabilities for 10 years, with the latest figure at $284.0 million in Q2 2026.
- Other Non-Current Liabilities for Q2 2026 came in at $284.0 million, up 2.9% year-over-year; the trailing twelve-month figure through Jun 2026 was $284.0 million (up 2.9% YoY), and the FY2025 annual result was $285.0 million, up 6.74% from the prior year.
- Other Non-Current Liabilities held at $284.0 million in Q2 2026, from $283.0 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $285.0 million in Q4 2025 and troughed at $81.0 million in Q3 2022.
- A 5-year average of $218.8 million and a median of $264.0 million in 2024 frame the typical range for Other Non-Current Liabilities.
- The widest annual swing landed in 2022, when Other Non-Current Liabilities surged 11200.0%; it then gained 1.81% in 2025.
- A 5-year view of Other Non-Current Liabilities shows it stood at $135.0 million in 2022, then surged by 89.63% to $256.0 million in 2023, then gained by 4.3% to $267.0 million in 2024, then rose by 6.74% to $285.0 million in 2025, then slipped by 0.35% to $284.0 million in 2026.
- Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $284.0 million in Q2 2026, $283.0 million in Q1 2026, and $285.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Moderna | 25.26 Bn | 20.13 Bn | 52.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 284.00 Mn |
| Mar 31, 2026 | 283.00 Mn |
| Dec 31, 2025 | 285.00 Mn |
| Sep 30, 2025 | 281.00 Mn |
| Jun 30, 2025 | 276.00 Mn |
| Mar 31, 2025 | 274.00 Mn |
| Dec 31, 2024 | 267.00 Mn |
| Sep 30, 2024 | 276.00 Mn |
| Jun 30, 2024 | 266.00 Mn |
| Mar 31, 2024 | 262.00 Mn |
| Dec 31, 2023 | 256.00 Mn |
| Sep 30, 2023 | 172.00 Mn |
| Jun 30, 2023 | 173.00 Mn |
| Mar 31, 2023 | 163.00 Mn |
| Dec 31, 2022 | 135.00 Mn |
| Sep 30, 2022 | 81.00 Mn |
| Jun 30, 2022 | 113.00 Mn |
| Mar 31, 2022 | 91.00 Mn |
| Dec 31, 2021 | 76.00 Mn |
| Sep 30, 2021 | 1.00 Mn |